Risk factors of central nervous system relapse in mantle cell lymphoma
- 20 February 2013
- journal article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 54 (9), 1908-1914
- https://doi.org/10.3109/10428194.2013.767454
Abstract
Central nervous system (CNS) relapse has not been extensively studied in mantle cell lymphoma (MCL). We retrospectively analyzed the risk factors and pattern of CNS relapse in consecutive patients with MCL. We identified 142 cases of MCL treated from 1980 to 2011. Median age at diagnosis was 68 years; 82% of patients had advanced stage; extranodal disease was reported in 89% of cases and high serum lactate dehydrogenase (LDH) in 40%. Fourteen patients (10%) did not receive treatment at diagnosis. Chemotherapy was administered to 125 patients (88%), in 21 cases (15%) including drugs penetrating into the CNS or given intrathecally; 49 patients (35%) had rituximab. Ten patients had front-line autologous transplant. After a median follow-up of 7.9 years, CNS relapse occurred in 11 cases (7.8%) at a median of 13.8 months. Actuarial risk of CNS relapse was higher in patients with elevated LDH (p = 0.002), higher International Prognostic Index (IPI) score (p = 0.018) and blastoid histology (p < 0.0001). Blastoid histology retained significance at multivariate analysis. Median survival after CNS relapse was 6.3 months. No front-line treatment reduced the risk of CNS relapse. Our analysis confirms the poor outcome of MCL after CNS relapse and may allow the identification of patients needing prophylaxis of CNS relapse.Keywords
This publication has 22 references indexed in Scilit:
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood, 2011
- Central nervous system prophylaxis in mantle cell lymphomaBlood, 2009
- Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresBritish Journal of Haematology, 2009
- Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic optionsHematological Oncology, 2009
- Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group reportBlood, 2008
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood, 2008
- Secondary lymphomas of the central nervous system: risk, prophylaxis and treatmentLeukemia & Lymphoma, 2008
- What is the real risk of central nervous system involvement in mantle cell lymphoma?Leukemia & Lymphoma, 2008
- Update on the molecular biology of mantle cell lymphomaHematological Oncology, 2006
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958